Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade

Metastatic renal cell carcinoma (RCC) is a tumor entity with poor prognosis due to limited therapy options. Tyrosine kinase inhibitors (TKI) represent the standard of care for RCCs, however a significant proportion of RCC patients develop resistance to this therapy. Interleukin-6 (IL-6) is considere...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishibashi, Kei, Haber, Tobias, Breuksch, Ines, Gebhard, Susanne, Sugino, Takashi, Kubo, Hitoshi, Hata, Junya, Koguchi, Tomoyuki, Yabe, Michihiro, Kataoka, Masao, Ogawa, Soichiro, Hiraki, Hiroyuki, Yanagida, Tomohiko, Haga, Nobuhiro, Thüroff, Joachim W., Prawitt, Dirk, Brenner, Walburgis, Kojima, Yoshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589655/
https://www.ncbi.nlm.nih.gov/pubmed/28903416
http://dx.doi.org/10.18632/oncotarget.19420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589655/
https://www.ncbi.nlm.nih.gov/pubmed/28903416
http://dx.doi.org/10.18632/oncotarget.19420

Ejemplares similares